JP2025511161A5 - - Google Patents
Info
- Publication number
- JP2025511161A5 JP2025511161A5 JP2024557983A JP2024557983A JP2025511161A5 JP 2025511161 A5 JP2025511161 A5 JP 2025511161A5 JP 2024557983 A JP2024557983 A JP 2024557983A JP 2024557983 A JP2024557983 A JP 2024557983A JP 2025511161 A5 JP2025511161 A5 JP 2025511161A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305439 | 2022-04-04 | ||
| EP22305439.6 | 2022-04-04 | ||
| PCT/EP2023/058693 WO2023194310A1 (en) | 2022-04-04 | 2023-04-03 | Therapeutic combination of kras g12c inhibitor and tead inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025511161A JP2025511161A (ja) | 2025-04-15 |
| JP2025511161A5 true JP2025511161A5 (https=) | 2026-04-10 |
| JPWO2023194310A5 JPWO2023194310A5 (https=) | 2026-04-10 |
Family
ID=81326107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557983A Pending JP2025511161A (ja) | 2022-04-04 | 2023-04-03 | Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250295664A1 (https=) |
| EP (1) | EP4504203A1 (https=) |
| JP (1) | JP2025511161A (https=) |
| CN (1) | CN118973584A (https=) |
| WO (1) | WO2023194310A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7039489B2 (ja) | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| WO2018119183A2 (en) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| EA201992781A1 (ru) | 2017-05-22 | 2020-04-01 | Эмджен Инк. | Ингибиторы g12c kras и способы их применения |
| HRP20230377T1 (hr) | 2017-11-15 | 2023-06-23 | Mirati Therapeutics, Inc. | Inhibitori mutacije kras g12c |
| WO2019213516A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2020055761A1 (en) * | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| TW202128699A (zh) * | 2019-11-27 | 2021-08-01 | 美商建南德克公司 | 治療性化合物 |
| US20230140808A1 (en) | 2020-04-07 | 2023-05-04 | Sanofi | (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer |
| US11787775B2 (en) * | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| JP7774612B2 (ja) | 2020-07-30 | 2025-11-21 | サノフイ | アクリルアミド置換インダン化合物およびその治療的使用 |
-
2023
- 2023-04-03 EP EP23713397.0A patent/EP4504203A1/en active Pending
- 2023-04-03 CN CN202380032305.8A patent/CN118973584A/zh active Pending
- 2023-04-03 JP JP2024557983A patent/JP2025511161A/ja active Pending
- 2023-04-03 WO PCT/EP2023/058693 patent/WO2023194310A1/en not_active Ceased
- 2023-04-03 US US18/852,884 patent/US20250295664A1/en active Pending